All In Biotech

Drug Trial Radar · NCT07930338

First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma

Phase 1 Dose-escalation Study of YG-01 in Patients With Glioblastoma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Apr 2028

Study completion Nov 2029

Sponsor

Lead sponsor
YGION Biomedical GmbHIndustry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.

Conditions

  • Glioblastoma

Interventions

  • YG-01 Dose Level 1Biological

    YG-01 administered subcutaneously at Dose Level 1 according to the study treatment schedule.

  • YG-01 Dose Level 2Biological

    YG-01 administered subcutaneously at Dose Level 2 according to the study treatment schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of local and systemic adverse events within 7 days following each administration of YG-01Time frame: From baseline until 7 days after each YG-01 administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University Vienna

    Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.